Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Andrew Zelenetz, MD, provides the clinical progress and outcomes to date with the BOVen trial in CLL

Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, provides the clinical progress and outcomes to date with the BOVen trial investigating zanabrutinib, Obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia (CLL) patients

Tags: ASCO Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 23 July 2020

Recent Videos: Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

video

Andrew Zelenetz, MD, provides the clinical progress and outcomes to date with the BOVen trial in CLL

Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, provides the clinical progress and outcomes to date with the BOVen ...

video

Jorge Cortes, MD, on the evolution of CAR-T cell therapies in hematologic malignancies management

Dr. Cortes, Director, Georgia Cancer Center, explains the evolution of CAR-T cell therapies in the management of hematologic malignancies and ...

video

Jorge Cortes, MD, discusses the take home message from the OPTIC study in CML patients for HCPs

Dr. Cortes, Director, Georgia Cancer Center, discusses the take home message from the OPTIC study in chronic lymphocytic leukemia (CML) ...

video

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patients

Dr. Cortes, Director, Georgia Cancer Center, provides thoughts on what the impact of the OPTIC study will be on chronic ...

video

Jorge Cortes, MD, tells us about the OPTIC study, a phase 2 investigation of ponatinib in CML

Dr. Cortes, Director, Georgie Cancer Center, tells us about the OPTIC study, a phase 2 investigation of ponatinib in chronic ...

video

Tanya Siddiqi, MD, elaborates on outcomes from the Phase 2 CAPTIVATE study presented at ASH '19

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on ...

video

Tanya Siddiqi, MD, regarding the Transcend-NHL data investigating CAR-T cell therapy in CLL

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions ...

video

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, describes the landscape of mutations and targeted therapy in acute ...

video

Richard Stone, MD, provides opinion on whether all AML patients should be tested for FLT3 mutations

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, provides opinion on whether all acute myeloid leukemia (AML) patients ...

video

Richard Stone, MD, elaborates on prognostic factors and the relationship to outcomes in AML

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, elaborates on prognostic factors and the relationship to outcomes in ...

Related Videos

video-image

Jorge Cortes, MD, on the evolution of CAR-T cell therapies in hematologic malignancies management

video-image

Jorge Cortes, MD, discusses the take home message from the OPTIC study in CML patients for HCPs

video-image

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patients

video-image

Jorge Cortes, MD, tells us about the OPTIC study, a phase 2 investigation of ponatinib in CML

video-image

Tanya Siddiqi, MD, elaborates on outcomes from the Phase 2 CAPTIVATE study presented at ASH '19

video-image

Tanya Siddiqi, MD, regarding the Transcend-NHL data investigating CAR-T cell therapy in CLL

video-image

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

video-image

Richard Stone, MD, provides opinion on whether all AML patients should be tested for FLT3 mutations

video-image

Richard Stone, MD, elaborates on prognostic factors and the relationship to outcomes in AML

video-image

Richard Stone, MD, offers his impression of the landscape for FLT3 inhibition in AML

video-image

Richard Stone, MD, shares thoughts on current treatment strategies for elderly AML patients

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

video-image

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

video-image

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

video-image

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Chaitra Ujjani, MD, tells us about the results of the Phase 3 ELEVATE TN study in CLL

video-image

Chaitra Ujjani, MD, offers her impression of the Phase 2 CAPTIVATE study in CLL

video-image

Amer Zeidan, MBBS, elaborates on the role of venetoclax in treatment of MDS

video-image

Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia

video-image

Shyamala Navada, MD, MSCR, offers opinion on how the treatment landscape of MDS is evolving

video-image

Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19

video-image

John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors

video-image

Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Courtney DiNardo, MD, describes the targeted therapy landscape in acute myeloid leukemia

video-image

Courtney DiNardo, MD, regarding the evolution of treatment in acute myeloid leukemia

video-image

Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AML

video-image

John Seymour, MBBS, PHD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

John Seymour, MBBS, PHD, elaborates on the updated data from the Phase 3 MURANO trial

video-image

Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia

video-image

Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma

video-image

Saro Armenian, DO, MPH, on bone marrow transplant survivorship outcomes in AML patients

video-image

James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019

video-image

James McCloskey, MD, considers how the role of molecular profiling in AML is changing

video-image

James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19

video-image

James McCloskey, MD, shares his impression of the Phase 3 ASCERTAIN trial in MDS

video-image

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

video-image

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

video-image

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

video-image

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

video-image

Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

video-image

Paul M. Barr, MD, on data from the CLL-14 trial in chronic lymphocytic leukemia

video-image

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

video-image

Daniel J. DeAngelo, MD, PhD, comments on how to manage MDS patients ineligible for transplant

video-image

Daniel J. DeAngelo, MD, PhD, considers the implications of the recent wave of approvals in AML

video-image

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

video-image

Naiyer Rizvi, MD, explains the role of biomarkers in lung cancer treatment planning

video-image

Daniel J. DeAngelo, MD, PhD, on the latest data involving uproleselan with chemotherapy in AML

video-image

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

video-image

Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL

video-image

Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL

video-image

Yana Pikman, MD, regarding research outcomes from the LEAP Consortium

video-image

Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia

video-image

Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia

video-image

Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch

video-image

Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

video-image

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

video-image

Keith Pratz, MD, on genetic testing in AML prior to the start of therapy

video-image

Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL

video-image

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018

video-image

Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018

video-image

Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3

video-image

Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML

video-image

James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML

video-image

James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia

video-image

James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients

video-image

James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML

video-image

James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3

video-image

Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML

video-image

John Burke, MD, elaborates on the Beat AML umbrella study

video-image

John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML

video-image

John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens

video-image

John Burke, MD, speaks to the reliability of the FLT3 mutation test

video-image

John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment

video-image

Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients

video-image

Ravi Vij, MD, on molecular testing and acute myelogenous leukemia

video-image

Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome

video-image

Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML

video-image

Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018

video-image

Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia

video-image

Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL

video-image

Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax

video-image

Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients

video-image

Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)

video-image

James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML

video-image

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

video-image

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

video-image

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

video-image

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

video-image

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

video-image

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

video-image

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

video-image

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

video-image

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

video-image

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

video-image

Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations

video-image

Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL

video-image

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

video-image

Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017

video-image

Jeff Sharman, MD, comments on emerging trends in CLL management

video-image

Aref Al-Kali, MD, on how hematologists will adopt midostaurin for FLT3+ AML patients

video-image

Aref Al-Kali, MD, on the data coming out of ASCO 2017 regarding FLT3 mutant AML patients

video-image

Aref Al-Kali, MD, offers perspective on treating elderly AML patients

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

video-image

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

video-image

Mark Levis, MD, on why the FLT3 target is important in AML

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

video-image

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

video-image

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the Quantum First Study

video-image

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

video-image

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

video-image

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

video-image

Alexander Perl, MD, discusses the Quantum First Study and potential implications

video-image

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

video-image

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

video-image

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

video-image

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

video-image

Mark Levis, MD, discusses significance of the Quantum-R study

video-image

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

video-image

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

video-image

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

video-image

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

video-image

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

video-image

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL

video-image

Leslie Popplewell, MD, provides perspective on the ELARA study investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies

video-image

Leslie Popplewell, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

video-image

Leslie Popplewell, MD, provides thoughts on the role Yescarta (axicabtagene ciloleucel) will play in low grade NHL management

video-image

Leslie Popplewell, MD, on impressions of the Alexander trial investigating AUTO3(CAR-T cell therapy) as DLBCL treatment

video-image

Leslie Popplewell, MD, discusses the potential practice changing outcomes of the Keynote-204 study presented at ASCO20

video-image

Roy Herbst, MD, PhD, provides thoughts on stereotactic radiation plus TKI therapy regarding NSCLC

video-image

Andrew Zelenetz, MD, describes the study presented at ASCO 20 exploring the CIBMTR analysis of PET scans

video-image

Andrew Zelenetz, MD, discusses the validity and availability of the EZH2 companion diagnostic test

video-image

Andrew Zelenetz, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

video-image

Andrew Zelenetz, MD, shares some of the unique aspects in the clinical design of the BOVen study

video-image

Andrew Zelenetz, MD, examines whether Yescarta (axicabtagene ciloleucel) will play a significant role in low grade NHL management

video-image

Andrew Zelenetz, MD, shares impressions of the Alexander trial investigating AUTO3 as treatment for DLBCL

video-image

Andrew Zelenetz, MD, provides thoughts on the potential practice changing outcomes of the Keynote-204 study

video-image

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC

video-image

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

video-image

Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel

video-image

Rana McKay, MD, dissects the pros and cons of the virtual format of ASCO20

video-image

Rana McKay, MD, elaborates on the advent of hormonal agents for patients with metastatic prostate cancer

video-image

Rana McKay, MD, explains approach to treating 2nd-line RCC patients who have received I-O combination

video-image

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

video-image

Rana McKay, MD, shares the design and outcomes of the Javelin Bladder 100 study

video-image

Robert Coleman, MD, describes experience with virtual ASCO20

video-image

Joyce Liu, MD, describes experience with virtual ASCO20

video-image

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin

video-image

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

video-image

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

video-image

Robert Dreicer, MD, updates us on the role of cabazitaxel from the CARD study

video-image

Robert Dreicer, MD, on the utilization of PSMA PET scanning & biomarkers in prostate cancer

video-image

Robert Dreicer, MD, provides results presented concerning PSMA-linked 177Lutethium regarding mCRPC

video-image

Robert Dreicer, MD, describes the results of the Javelin-100 Bladder cancer trial

video-image

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

video-image

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

video-image

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

video-image

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

video-image

Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line renal cell carcinoma patients

video-image

Toni Choueiri, MD, describes treatment strategies for 2nd line renal cell carcinoma

video-image

Dana Chase, MD, FACOG, shares thoughts on the role of I-O in GTT management

video-image

Dana Chase, MD, FACOG, provides thoughts on the clinical evidence of secondary cytoreductive surgery

video-image

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study

video-image

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer

video-image

Derek Raghavan, MD, examines the projected cost of new GNRH antagonist therapy and its implications

video-image

Derek Raghavan, MD, discusses the efficacy and utility of the new GNRH antagonist, Reugolix

video-image

Derek Raghavan, MD, explains toxicities and factors determining GNRH-based therapies selection

video-image

Derek Raghavan, MD, provides a general overview of prostate cancer therapies

video-image

Derek Raghavan, MD, on the role of nephrectomy in the age of targeted therapies and immunotherapy

video-image

Derek Raghavan, MD, discusses Mobile screening Chest CT project for use in underserved populations

video-image

Toni Choueiri, MD, provides observations into the dynamic field of kidney cancer

video-image

Toni Choueiri, MD, considers the next steps in the further development of HIF-2 inhibitors

video-image

Toni Choueiri, MD, makes predictions for triplet combinations in the treatment of RCC

video-image

Toni Choueiri, MD, discusses approach to first line treatment of clear cell renal cell cancers

video-image

Toni Choueiri, MD, provides updates on HIF-2 alpha inhibitors in renal call cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, provides updates on PSMA radioligands for PET imaging

video-image

Nicholas Vogelzang, MD, discusses re-emergence of dose reduced cabozantinib + alezotuzumab in advanced prostate cancer

video-image

Nicholas Vogelzang, MD, provides thoughts on the role of radium 223 in management of advanced metastatic prostate cancer

video-image

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in metastatic prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, considers the dosing effects of cabazitaxel in clinical studies

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on CARD study impressions comparing novel hormonal therapy to cabazitaxel

video-image

Nicholas Vogelzang, MD, FASCO, FACP, updates us on the status of PSMA-linked radiopharmaceuticals

video-image

Marcia Brose, MD, PhD, provides opinion on who should be tested TRK fusions

video-image

Marcia Brose, MD, PhD, expounds on what should be done for patients who progress on larotrectinib

video-image

Marcia Brose, MD, PhD, on biopsy requirements for optimal evaluation for actionable TRK fusions

video-image

Marcia Brose, MD, PhD, describes how testing for TRK abnormalities are accomplished

video-image

Marcia Brose, MD, PhD, discusses the dosing, safety and efficacy of larotrectinib reported at ASCO20

video-image

Marcia Brose, MD, PhD, provides an overview of TRK fusion treatment in cancer patients

video-image

Tomasz Beer, MD, FACP, discusses the recently FDA approved relugolix

video-image

Tomasz Beer, MD, FACP, provides preliminary data presented concerning androgen receptor degraders

video-image

Tomasz Beer, MD, FACP, on how to treat patients who are progressing on androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, explains which nmCRPC patients to treat with androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, reviews updates concerning androgen receptor inhibitors in nmCRPC

video-image

Edward Garon MD, expounds on the new FDA approval of erlotinib + ramuciramab in EGFR positive advanced non-small cell lung cancer (NSCLC)

video-image

Edward Garon, MD, examines the ADAURA clinical study regarding adjuvant treatment in NSCLC

video-image

Edward Garon, MD, examines dual immunotherapy approach in the CITYSCAPE trial

video-image

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

video-image

Andres Poveda, MD, provides perspective on the digital format of ASCO20

video-image

Andres Poveda, MD, considers the role of PARP inhibitors in advanced ovarian cancer

video-image

Andres Poveda, MD, discusses the BRCA mutation and homologous recombination deficiency

video-image

Andres Poveda, MD, shares design and outcomes of the PHASE 3 SOLO2 regarding ovarian cancer

video-image

Nancy Lin, MD, on impressions of the Phase 2 study done the by the Translational Breast Cancer Consortium

video-image

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

video-image

Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer

video-image

Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer

video-image

Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard

video-image

Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer

video-image

Danny Rischin, MD, considers whether Libtayo (cemiplimab) is a standard of care in advanced CSCC

video-image

Danny Rischin, MD, discusses unmet needs and how advanced CSCC was treated prior to cemiplimab

video-image

Danny Rischin, MD, shares long-term outcomes of the clinical study regarding advanced CSCC

video-image

Scott Tagawa, MD, elaborates on what may account for resistance to PSMA radioligand therapies

video-image

Scott Tagawa, MD, explains how PSMA PET imaging is utilized with PSMA-based therapies

video-image

Scott Tagawa, MD, defines the 177Lutethium Beta emitter and the 225Actinium Alpha emitter PMSA-linked therapies

video-image

Scott Tagawa, MD, considers next steps in the development of the PSMA-targeted alpha emitter in mCRPC

video-image

Scott Tagawa, MD, discusses the results of Phase I dose-escalation study regarding mCRPC

video-image

Daneng Li, MD, considers the role of cabozantinib and other TKIs as HCC patients progress on I-O

video-image

Daneng Li, MD, discusses the recent FDA approval of combining atezolizumab + bevacizumab in HCC

video-image

Daneng Li, MD, on the study results investigating the geriatric assessment tool & chemo side effects

video-image

Daneng Li, MD, describes the geriatric assessment tool developed at City of Hope

video-image

Shaji Kumar, MD, discusses excitement about bispecific antibodies in multiple myeloma

video-image

Shaji Kumar, MD, provides perspective on the role of anti-CD38 antibodies changing multiple myeloma

video-image

Shaji Kumar, MD, shares the design and outcomes of the CARTITUDE-1 trial regarding multiple myeloma

video-image

Shaji Kumar, MD, shares the take home message for physicians treating 1st line multiple myeloma

video-image

Roy Herbst, MD, PhD, discusses next steps in clinical development of osimertinib in adjuvant NSCLC

video-image

Roy Herbst, MD, PhD, explains the 3-year length of adjuvant treatment strategy in ADAURA

video-image

Roy Herbst, MD, PhD, considers assessing NSCLC patients who recur after completing adjuvant osimertinib(Tagrisso)

video-image

Xiuning Le, MD, PhD, describes experience with virtual ASCO20

video-image

Xiuning Le, MD, PhD, shares impressions of the randomized Phase 2 CITYSCAPE study regarding NSCLC

video-image

Xiuning Le, MD, PhD, describes the ADAURA clinical study as an adjuvant treatment in NSCLC

video-image

Xiuning Le, MD, PhD, considers tepotinib development going forward as a result of the VISION study

video-image

Dana Chase, MD, FACOG, considers the role of PARP inhibitors in advanced ovarian cancer today

video-image

Dana Chase, MD, FACOG, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

video-image

Xiuning Le, MD, PhD, discusses testing for METex14 skipping and validating it in the VISION study

video-image

Xiuning Le, MD, PhD, discusses the mechanism of action for tepotanib and how it targets NSCLC

video-image

Bruce Feinberg, DO, elaborates on surprising findings in Oncology Insights 7th edition study

video-image

Bruce Feinberg DO, explains strategies that are or should be provided for managing cancer survivors

video-image

Bruce Feinberg, DO, provides examples of social determinants of health and how they qualify as this

video-image

Bruce Feinberg, DO, discusses the importance of social determinants to the health of cancer patients' outcomes

video-image

Joyce Liu, MD, provides perspective on the large studies in advanced ovarian cancer

video-image

Joyce Liu, MD, on overall survival outcomes of Phase 3 SOLO2 study regarding advanced ovarian cancer

video-image

Joyce Liu, MD, shares thoughts on the activity of the Wee1 inhibitor as monotherapy in USC

video-image

Joyce Liu, MD, provides good news, in spite of Phase 3 NRG-GY004 study being negative

video-image

Joyce Liu, MD, summarizes the outcomes of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Joyce Liu, MD, provides background and design of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, describes the overall survival outcomes of the Phase 3 SOLO2 clinical study

video-image

Robert Coleman, MD, FACOG, FACS, explains the underlying biology of homologous recombination deficiency

video-image

Robert Coleman, MD, FACOG, FACS, discusses the 2 recent FDA approvals for PARP inhibitors in ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, provides thoughts on the NRG-GY004 phase III study

video-image

Robert Coleman, MD, FACOG, FACS, shares conclusions that can be drawn from phase 3 GOG213 study at ASCO20

video-image

Salvatore Siena, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients

video-image

Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development

video-image

Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients

video-image

Sankalp Sethi & Jeffrey Patton, MD, on how pharma can help community oncology’s COVID-19 challenges

video-image

Constantine Tam, MD, & Robert Figlin, MD, FACP, discuss progress in Waldenstrom’s Macroglobulinemia & ASCO20

video-image

Tanios Bekaii-Saab, MD, FACP, considers the emerging role of immunotherapy in advanced CRC treatment

video-image

Tanios Bekaii-Saab, MD, FACP, discusses oral chemotherapy in adjuvant and advanced CRC treatment during the COVID era

video-image

Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer

video-image

Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely to respond to I-O

video-image

Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer

video-image

Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer

video-image

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

video-image

Matthew Galsky, MD, considers a new standard of maintenance with the Javelin study outcomes

video-image

Matthew Galsky, MD, shares the design and outcomes of the Javelin Bladder 100 study

video-image

Matthew Galsky, MD, explains which biomarkers likely have the most predictive value

video-image

Matthew Galsky, MD, tells us about the Phase 3 IMvigor130 study in advanced urothelial cancer

video-image

Bruce Feinberg, DO, on the understanding medical oncologists have on social determinants of health

video-image

Shaji Kumar, MD, shares results of the Phase 3 study regarding 1st line multiple myeloma treatment

video-image

Roy Herbst, MD, PhD, shares perspective on the plenary session presentation of the ADAURA study

video-image

Xiuning Le, MD, PhD, discusses goals and results of the VISION study in non-small cell lung cancer

video-image

Howard Hochster, MD, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in CRC patients

video-image

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers

video-image

Howard Hochster, MD, on whether atezolizumab + bevacizumab regimen is a new standard in care in HCC

video-image

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers

video-image

Howard Hochster, MD, provides thoughts on the potential practice changing results of the Keynote-177 study

video-image

Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC

video-image

Alan Venook, MD, provides opinions of the OPRA data in rectal cancer patients presented at ASCO20

video-image

Alan Venook, MD, on potential new standard in care post approval of atezolizumab + bevacizumab

video-image

Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers

video-image

Alan Venook, MD, considers how I-O is evolving towards the first line treatment of colorectal cancer

video-image

Alan Venook, MD, describes the potential practice changing results of the Keynote-177 study

video-image

Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC

video-image

Alan Venook, MD, discusses uniqueness of MSI-High/mismatch repair deficient CRC patients

video-image

Katie Kelley, MD, provides thoughts on the potential practice changing Study 22 results

video-image

Saad Usmani, MD, shares perspective on the addition of elotuzimab in multiple myeloma

video-image

Elizabeth Plimack, MD, explains how to identify patients who are good candidates for I-O in bladder cancer

video-image

Saad Usmani, MD, discusses the promise bispecific antibodies may hold in multiple myeloma management

video-image

Yuanbin Chen, MD, explains the impact of the 2nd arm in the CASPIAN study in small cell lung cancer

video-image

Katie Kelley, MD, differentiates the HIMALAYA study from Study 22 and I-O adoption in HCC treatment

video-image

Yuanbin Chen, MD, discusses the potential practice changing outcomes of the CASPIAN trial

video-image

Elizabeth Plimack, MD, on differentiating 1st line RCC patients when selecting a combination regimen

video-image

Katie Kelley, MD, explains the design of the Phase 2 Study 22 investigating tremelimumab + Imfinzi (durvalumab) in hepatocellular cancer (HCC) patients

video-image

Saad Usmani, MD, on impressions of the CARTITUDE study in relapsed/refractory multiple myeloma patients

video-image

Saad Usmani, MD, shares what impresses him about the BOSTON study in multiple myeloma patients after 1 to 3 prior therapies

video-image

Elizabeth Plimack, MD, describes her ASCO20 experience in the virtual setting

video-image

Elizabeth Plimack, MD, on treating 2nd line RCC patients that have received an I-0 combination in the 1st line setting

video-image

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

video-image

Charles Rudin, MD, PhD, discusses the Keynote-604 study and the role of Keytruda in ES-SCLC

video-image

Karen Lu, MD, discusses how PARP inhibitors have changed the management of advanced ovarian cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling

video-image

Jesus Berdeja, MD, explains how BCMA targeting differs from other CAR-T cell therapies

video-image

Jesus Berdeja, MD, describes the evolving role of CAR-T therapies in multiple myeloma

video-image

Eric Jonasch, MD, discusses the incidence of Von Hippel-Lindau Disease among RCC patients

video-image

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

video-image

Eric Jonasch, MD, explains the development process for MK-6482 and hopes for future studies

video-image

Eric Jonasch, MD, on the 4 year Checkmate-214 follow up investigating nivolumab + ipilimumab

video-image

Eric Jonasch, MD, considers the combination and/or sequencing IO and TKIs in advanced RCC management

video-image

Eric Jonasch, MD, recognizes interesting clinical presentations regarding RCC management at ASCO20

video-image

Fred Saad MD, on SPARTAN study highlights for oncologists that do not specialize in prostate cancer

video-image

Fred Saad, MD, on genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Fred Saad, MD, shares impressions of the CARD study investigating cabazitaxel in nmCRPC patients

video-image

Fred Saad, MD, details safety concerns when prescribing apalutamide + ADT to nmCRPC patients

video-image

Katie Kelley, MD, discusses fitting tremelimumab + durvalumab into HCC treatment algorithms

video-image

Saad Usmani, MD, outlines the Phase 1 study investigating teclistamab in relapsed/refractory multiple myeloma

video-image

Elizabeth Plimack, MD, explains the design and outcomes of the Phase 3 randomized Keynote 426 study

video-image

Yuanbin Chen, MD, shares outcomes of the Phase 3 CASPIAN trail investigating Imfinzi (durvalumab) + chemotherapy

video-image

Vivek Subbiah, MD, on the FDA approved product, selpercatanib, for RET-driven lung and thyroid cancers

video-image

Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities it may have to other targeted therapy tests

video-image

Charles Rudin, MD, PhD, shares outcomes of the Keynote 604 study investigating the combination of Keytruda and chemotherapy in ES-small cell lung cancer patients

video-image

Vivek Subbiah, MD, on developing targeted therapies for RET fusion + solid tumors and the effectivity

video-image

Vivek Subbiah, MD, describes the incidence of RET fusion + solid tumors amongst cancer patients and when RET-fusion + targeted therapies will be most effective

video-image

Karen Lu MD, elaborates on the underlying biology of homologous recombination deficiency (HRD) and how it applies to ovarian cancer management

video-image

Jesus Berdeja, MD, shares the design and outcomes of the CARTITUDE-1 trial investigating the BCMA-targeted CAR-T cell therapy JNJ-4528 in relapsed/refractory multiple myeloma patients

video-image

Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in

video-image

Fred Saad, MD, shares the design and outcomes of the SPARTAN study in patients with nmCRPC

video-image

Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

video-image

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agents

video-image

Sandip Patel, MD, speculates on the impact of the RELAY trial presented at ASCO 2019

video-image

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

video-image

Che-Kai Tsao, MD, discusses the current application of biomarkers in renal cell carcinoma

video-image

Saad Usmani, MD, FACP, considers data in smoldering MM coming out of ASCO 2019

video-image

Parameswaran Hari, MD, speculates on whether KRD will replace stem cell transplant

video-image

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

video-image

Shirish Madhav Gadgeel, MBBS, on treating patients who have already received PD-L1 targeting agents

video-image

Che-Kai Tsao, MD, on deciding between I-O + TKIs combinations indicated for the treatment of RCC

video-image

Philip Philip MD, PhD, FRCP, on the APACT trial in surgically resected pancreatic adenocarcinoma

video-image

Sandip Patel, MD, describes the ideal patient to receive Alimta + Keytruda based on Keynote-189

video-image

Lowell L. Hart, MD, FACP, explains the mechanism of action for trilaciclib

video-image

Parameswaran Hari, MD, discusses the role of CAR-T therapy in multiple myeloma

video-image

Shirish Madhav Gadgeel, MBBS, offers opinion on the results of the RELAY trial from ASCO 2019

video-image

Josep Tabernero, MD, PhD, speculates on exciting clinical trial outcomes in gastric cancer

video-image

Tomasz M. Beer MD, FACP, considers the role of metformin in castrate-resistant prostate cancer

video-image

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

video-image

Lowell L. Hart, MD, FACP, regarding recent data investigating trilaciclib in SCLC

video-image

Parameswaran Hari, MD, considers whether isatuximab will become a viable option in MM

video-image

Shirish Madhav Gadgeel, MBBS, on the ideal patient to receive Alimta + Keytruda based on Keynote-189

video-image

Robert A. Figlin, MD, speculates on clinical advances in renal cell carcinoma

video-image

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

video-image

Nancy A. Dawson, MD, regarding preferred agents in the 2nd line setting in renal cell carcinoma

video-image

Paul M. Barr, MD, considers the role of CAR-T therapy in B-cell lymphomas

video-image

Michael B. Atkins, MD, on the role of IMDC classification in treatment decision-making

video-image

Tomasz M. Beer MD, FACP, on the efficacy of abiraterone + enzalutamide in mCRPC

video-image

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC

video-image

Marwan G. Fakih, MD, on whether KRAS amplification predicts resistance to EGFR therapies

video-image

Nancy A. Dawson, MD, on selecting the appropriate I-O + TKI combo in the treatment of 1st line RCC

video-image

Vincent Chung, MD, shares details from the APACT study in pancreatic adenocarcinoma

video-image

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

video-image

Michael B. Atkins, MD, comments on clinical trials investigating the use of I-O and TKIs in RCC

video-image

Saad Usmani, MD, FACP, regarding outcomes from the MAIA study presented at ASCO 2019

video-image

Che-Kai Tsao, MD, considers the various I-O and TKI combinations available for 1st line RCC

video-image

Josep Tabernero, MD, PhD, provides perspective on the POLO trial in pancreatic

video-image

Philip Philip MD, PhD, FRCP, on BRCA gene mutations & outcomes in pancreatic cancer

video-image

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Kristin Higgins, MD, offers opinion on the PACIFIC study in non-small cell lung cancer

video-image

Parameswaran Hari, MD, considers the implications of the CASSIOPEIA trial

video-image

Marwan G. Fakih, MD, regarding outcomes from the AMG 510 study

video-image

Shirish Madhav Gadgeel, MBBS, on treating non-squamous NSCLC patients expressing high PD-L1

video-image

Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Nancy A. Dawson, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Vincent Chung, MD, elaborates on BRCA mutations and pancreatic cancer

video-image

Tomasz M. Beer MD, FACP, tells us about the ENZAMET study in mHSPC

video-image

Michael B. Atkins, MD, considers preferred agents in the treatment of RCC in the 2nd line

video-image

Saad Usmani, MD, FACP, compares IV daratumumab and subcutaneous daratumumab

video-image

Che-Kai Tsao, MD, regarding the evolving landscape of metastatic clear cell RCC

video-image

Josep Tabernero, MD, PhD, offers perspective on Keynote-062 in advanced gastroesophageal

video-image

Philip Philip MD, PhD, FRCP, discusses outcomes from the POLO trial in pancreatic cancer

video-image

Sandip Patel, MD, comments on the top stories in lung cancer from ASCO 2019

video-image

Kristin Higgins, MD, shares her interpretation of the PACIFIC study in unresectable NSCLC

video-image

Parameswaran Hari, MD, elaborates on the outcome from the ECOG trial in SMM

video-image

Shirish Madhav Gadgeel, MBBS, regarding the top stories in lung cancer from ASCO 2019

video-image

Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC

video-image

Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer

video-image

Nancy A. Dawson, MD, regarding the ENZAMET study in mHSPC presented at ASCO '19

video-image

Vincent Chung, MD, shares outcomes from the POLO trial metastatic pancreatic cancer

video-image

Michael B. Atkins, MD, on selecting I-O and TKI combinations for the treatment of 1st line RCC

video-image

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

video-image

Andre Goy, MD, explains how lenalidomide will impact the management of FL and MZL

video-image

Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment

video-image

Andre Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Robert M. Rifkin, MD, FACP, speculates on the promise of bispecific antibodies in MM

video-image

Andre Goy, MD, shares the most exciting advances in lymphoma coming out of ASCO 2019

video-image

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer

video-image

Debra Patt, MD, MPH, MBA, outlines policies proposed to address drug pricing

video-image

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer

video-image

Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC

video-image

Robert M. Rifkin, MD, FACP, discusses maintenance regimens for multiple myeloma

video-image

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial

video-image

Debra Patt, MD, MPH, MBA, considers the transition from volume to value in the oncology space

video-image

Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer

video-image

Thomas A. Abrams, MD, outlines next steps if an HCC patient fails 1st line therapy with I-O

video-image

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab

video-image

Paul G. Richardson, MD, shares clinical results from the ECOG trial in smoldering MM

video-image

Debra Patt, MD, MPH, MBA, on the factors influencing cost in novel therapeutic interventions

video-image

Leonard Saltz, MD, shares outcomes from the APACT trial in pancreatic adenocarcinoma

video-image

Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximab

video-image

Paul G. Richardson, MD, considers whether isatuximab shows promise as a treatment option for MM

video-image

Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer

video-image

Talia Golan, MD, explains the role of biomarkers in the treatment of pancreatic cancer

video-image

Thomas A. Abrams, MD, offers thoughts on Keynote-062 in gastric/gastroesophageal cancer

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

video-image

Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer

video-image

Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumab

video-image

Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab

video-image

Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC

video-image

Talia Golan, MD, regarding the practice-changing potential of the POLO trial

video-image

Thomas A. Abrams, MD, elaborates on the outcomes from the APACT study

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

video-image

Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC

video-image

Robert M. Rifkin, MD, FACP, discusses outcomes from the ECOG trial in smoldering multiple myeloma

video-image

Paul G. Richardson, MD, regarding the updated FORTE trial data in multiple myeloma

video-image

Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial

video-image

Talia Golan, MD, elaborates on the outcomes from the POLO study presented at ASCO 2019

video-image

Thomas A. Abrams, MD, provides perspective on the POLO trial in metastatic pancreatic cancer

video-image

Naiyer Rizvi, MD, speculates on the future of drug development in NSCLC

video-image

William Oh, MD, tells us about the results of Keynote-365 in mCRPC

video-image

Naiyer Rizvi, MD, offers thoughts on the role of blood TMB vs. tissue TMB

video-image

William Oh, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

video-image

Naiyer Rizvi, MD, describes the role of PD-L1 & TMB biomarkers in the treatment of lung cancer

video-image

William Oh, MD, considers the role of biomarker selection trials in prostate cancer

video-image

Andrew Goy, MD, explains how the approval of lenalidomide will impact the management of FL & MZL

video-image

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

video-image

Naiyer Rizvi, MD, tells us about the results of Keynote-001 in NSCLC

video-image

William Oh, MD, shares the differences between the ENZAMET and TITAN studies

video-image

Andrew Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial

video-image

William Oh, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Andrew Goy, MD, elaborates on the most exciting recent clinical advances in lymphoma

video-image

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

video-image

Bradley McGregor, MD, considers strategies for treating 2nd line RCC patients

video-image

Ravi Salgia, MD, PhD, considers the unmet medical needs in the treatment of NSCLC

video-image

Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

video-image

Ravi Salgia, MD, PhD, on the ideal patient to receive Alimta plus Keytruda based on Keynote-189

video-image

Lori A. Leslie, MD, on the recent data regarding umbralisib in relapsed/refractory lymphoma

video-image

Lori A. Leslie, MD, speculates on how CAR-T cell therapy may be combined to treat lymphomas

video-image

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

video-image

Ravi Salgia, MD, PhD, on treating non-squamous, NSCLC patients with high levels of PD-L1

video-image

Tian Zhang, MD, discusses the most anticipated trial results regarding biomarkers in RCC

video-image

Ravi Salgia, MD, PhD, offers strategies for identifying PD-L1 status

video-image

Danny Rischin, MD, MBBS, FRACP, shares updated data from ASCO '19 investigating cemiplimab in cSCC

video-image

Tian Zhang, MD, regarding strategies for treating RCC in the 2nd line setting

video-image

Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC

video-image

Danny Rischin, MD, MBBS, FRACP, on the importance of the stratification by PD-L1 score

video-image

Tian Zhang, MD, offers perspective on treating newly diagnosed RCC patients

video-image

Ravi Salgia, MD, PhD, comments on germline mutations & the impact on NSCLC patients

video-image

Danny Rischin, MD, MBBS, FRACP, shares thoughts on Keynote-048 presented at ASCO 2019

video-image

Bradley McGregor, MD, considers the optimal approach to treating newly diagnosed RCC patients

video-image

Richard S. Finn, MD, speculates on the next phase of HCC management and research

video-image

Imane El Dika, MD, outlines next steps if an HCC patient fails 1st line therapy

video-image

Edward B. Garon, MD, on the implications of Keynote-189

video-image

Richard S. Finn, MD, outlines the next steps if an HCC patient fails 1st line therapy

video-image

Imane El Dika, MD, considers the role of I-O in the management of HCC

video-image

Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

video-image

Richard S. Finn, MD, offers opinion on the broader role of I-O in the management of HCC

video-image

Imane El Dika, MD, elaborates on the outcomes of Keynote-240 presented at ASCO 2019

video-image

Edward B. Garon, MD, considers the implications of Keynote-001 in advanced NSCLC

video-image

Richard S. Finn, MD, regarding outcomes from Keynote-240 in 1st line HCC

video-image

Pasi A. Jänne, MD, PhD, regarding the unmet medical needs in the treatment of NSCLC

video-image

Daneng Li, MD, elaborates on the COSMIC-312 trial in hepatocellular carcinoma

video-image

Pasi A. Jänne, MD, PhD, discusses some of the challenges in managing NSCLC

video-image

Martin E. Gutierrez, MD, discusses some of the top challenges in managing NSCLC

video-image

Daneng Li, MD, describes next steps if an HCC patient fails 1st line I-O therapy

video-image

Bruce Feinberg, DO, speculates on the future of AI in oncology treatment centers

video-image

Amrita Krishnan, MD, considers whether KRD will replace stem cell transplant

video-image

Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda

video-image

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

video-image

Bruce Feinberg, DO, outlines some of the concerns that oncologists have regarding AI

video-image

Amrita Krishnan, MD, discusses the future of isatuximab in the treatment of relapsed/refractory MM

video-image

Pasi A. Jänne, MD, PhD, elaborates on outcomes from the RELAY trial

video-image

Martin E. Gutierrez, MD, discusses the implications of the RELAY trial from ASCO 2019

video-image

Bruce Feinberg, DO, on how AI may evolve as a clinical decision-making support tool

video-image

Amrita Krishnan, MD, regarding outcomes from the CASSIOPEIA trial presented at ASCO '19

video-image

Pasi A. Jänne, MD, PhD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Martin E. Gutierrez, MD, regarding the implications of the initial & updated results of Keynote-189

video-image

Bruce Feinberg, DO, on real-world examples of artificial intelligence applications in oncology

video-image

Kim Chi, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Amrita Krishnan, MD, tells us about the outcomes of the ECOG trial in SMM

video-image

Kim Chi, MD, provides perspective on biomarker selection trials in prostate cancer

video-image

Daneng Li, MD, considers the role of immuno-oncology in the management of HCC

video-image

Pasi A. Jänne, MD, PhD, on molecular testing prior to the treatment of advanced NSCLC

video-image

Martin E. Gutierrez, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Bruce Feinberg, DO, defines and considers artificial intelligence as a healthcare tool

video-image

Pasi A. Jänne, MD, PhD, on the study of U3-1402 in EGFR mutant NSCLC presented at ASCO 2019

video-image

Daneng Li, MD, tells us about the outcomes of Keynote 240 presented at ASCO 2019

video-image

Bradley McGregor, MD, on combo ipilimumab + nivolumab in variant histologies of bladder cancer

video-image

Lori A. Leslie, MD, on how CAR-T cell therapy has impacted the treatment of B-cell lymphomas

video-image

Kim Chi, MD, regarding the differences in design between the ENZAMET & TITAN studies

video-image

Tian Zhang, MD, on promising studies in sarcomatoid RCC & urothelial cancer from ASCO '19

video-image

Martin E. Gutierrez, MD, on the role of clinico-genomic data sharing in lung cancer treatment

video-image

Pasi A. Jänne, MD, PhD, on advances in the treatment of lung cancer being presented at ASCO 2019

video-image

Ravi Salgia, MD, PhD, offers opinion on the top challenges in managing NSCLC

video-image

Bruce Feinberg, DO, considers how artificial intelligence may help practices become more efficient

video-image

Tian Zhang, MD, shares thoughts on the PDIGREE trial in metastatic, untreated RCC

video-image

Bradley McGregor, MD, on the data regarding enfortumab in post-platinum + I-O bladder cancer

video-image

Kim Chi, MD, regarding the TITAN study presented at ASCO 2019

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Novel Endpoints in Cancer Care: What Lies Ahead

video-image

Oncology Clinical Trials: Why We're Searching for Emerging Endpoints

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, regarding novel concepts in clinical trial design

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, shares his goals for the 2019 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image